{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T10:43:38Z","timestamp":1751625818524},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":482,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008108","name":"Taipei Tzu Chi Hospital","doi-asserted-by":"crossref","award":["[TCRD-TPE-101-17 and TCRD-TPE-103-35]"],"award-info":[{"award-number":["[TCRD-TPE-101-17 and TCRD-TPE-103-35]"]}],"id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jfma.2014.05.007","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T12:45:54Z","timestamp":1403700354000},"page":"716-721","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A pilot study of add-on oral hypoglycemic agents in treatment-na\u00efve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin"],"prefix":"10.1016","volume":"113","author":[{"given":"Ching-Sheng","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Jer","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Hsienhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding-Shinn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2014.05.007_bib1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/hep.21347","article-title":"Global challenges in liver disease","volume":"44","author":"Williams","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2014.05.007_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jfma.2011.05.005","article-title":"Transmission of hepatitis C virus by occupational percutaneous injuries in South Korea","volume":"111","author":"Ryoo","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2014.05.007_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jfma.2011.06.022","article-title":"Seroprevalence of hepatitis virus infection in men who have sex with men aged 18\u201340 years in Taiwan","volume":"111","author":"Tseng","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2014.05.007_bib4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2014.05.007_bib5","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2014.05.007_bib6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jfma.2013.08.013","article-title":"Extensive inflammation of actinic keratoses during interferon \u03b1 therapy for chronic hepatitis C in a Taiwanese albino woman","volume":"112","author":"Yang","year":"2013","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2014.05.007_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nm.3190","article-title":"Hepatitis C virus infection activates an innate pathway involving IKK-\u03b1 in lipogenesis and viral assembly","volume":"19","author":"Li","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jfma.2014.05.007_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0929-6646(10)60071-X","article-title":"Hepatitis C infection and metabolic syndrome","volume":"109","author":"Hsu","year":"2010","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2014.05.007_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/jgh.12024","article-title":"Fluvastatin helps interferon-based therapy in chronic hepatitis C: fact or fiction?","volume":"28","author":"Hsu","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2014.05.007_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/egh.12.24","article-title":"Genomic variation-guided management in chronic hepatitis C","volume":"6","author":"Hsu","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2014.05.007_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1572-0241.2006.01038.x","article-title":"Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2","volume":"102","author":"Kawaguchi","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2014.05.007_bib12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1440-1746.2009.06186.x","article-title":"Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection","volume":"25","author":"Hsu","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2014.05.007_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1053\/j.gastro.2010.11.002","article-title":"Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C","volume":"140","author":"Conjeevaram","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2014.05.007_bib14","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.23206","article-title":"Treatment of insulin resistance with metformin in na\u00efve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin","volume":"50","author":"Romero-G\u00f3mez","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2014.05.007_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2893.2005.00590.x","article-title":"Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan","volume":"12","author":"Lee","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2014.05.007_bib16","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/bmj.38050.593634.63","article-title":"Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study","volume":"328","author":"Kim","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2014.05.007_bib17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jhep.2006.01.004","article-title":"Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C","volume":"44","author":"Prati","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2014.05.007_bib18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2337\/diacare.23.1.57","article-title":"Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity","volume":"23","author":"Bonora","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2014.05.007_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1478-3231.2007.01626.x","article-title":"High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C","volume":"28","author":"Hsu","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2014.05.007_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/135965350901400101","article-title":"Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy","volume":"14","author":"Hsu","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jfma.2014.05.007_bib21","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2014.05.007_bib22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jhep.2008.12.017","article-title":"Insulin resistance predicts response to peginterferon-alpha\/ribavirin combination therapy in chronic hepatitis C patients","volume":"50","author":"Dai","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2014.05.007_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1478-3231.2009.02171.x","article-title":"Pioglitazone improves virological response to peginterferon alpha-2b\/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance","volume":"30","author":"Khattab","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2014.05.007_bib24","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1073\/pnas.1100349108","article-title":"Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy","volume":"108","author":"Hsu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jfma.2014.05.007_bib25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJMc1105515","article-title":"Boceprevir for chronic HCV genotype 1 infection","volume":"365","author":"Hsu","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.05.007_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/apt.12391","article-title":"Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan","volume":"38","author":"Hsu","year":"2013","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664614001788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664614001788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T15:25:13Z","timestamp":1689348313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664614001788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0929664614001788"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2014.05.007","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot study of add-on oral hypoglycemic agents in treatment-na\u00efve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2014.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier (Singapore) Pte Ltd.","name":"copyright","label":"Copyright"}]}}